
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. is positioned for sustained double-digit growth, supported by an expanding light adjustable lens (LDD) installed base and increased utilization rates. The company's strategic initiatives to enhance LAL volumes, coupled with an increase in gross margin guidance for 2025—from 72-74% to 76-77%—indicate a strong focus on profitability and operational efficiency. In addition, RxSight's recent revenue performance surpassed consensus expectations, which, along with management's optimistic outlook on key financial metrics, underscores a robust potential for future growth.
Bears say
RxSight Inc. has experienced a significant decline in its financial performance, with revenue dropping 14% year-over-year to $30.3 million and a substantial decrease in light delivery device (LDD) placements, falling 68% year-over-year and 38% quarter-over-quarter. The company’s monthly utilization rates for its light adjustable lenses (LALs) have also declined, indicating a troubling trend in demand, as these metrics fell to 8.0 LALs per LDD in 3Q25, down from 8.7 in 2Q25 and 10.1 in 3Q24. Additionally, management has acknowledged several risks, including limited adoption of their technology, disappointing commercial execution, and increased competition in the intraocular lens market, all of which cast doubt on the company's future growth prospects.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares